相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease
John A. Dougherty et al.
ANNALS OF PHARMACOTHERAPY (2021)
The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
Emmanuel Somm et al.
TRANSLATIONAL RESEARCH (2021)
Glucagon-Like Peptide-1 Receptor Agonists for Treatment of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: An Updated Meta-Analysis of Randomized Controlled Trials
Alessandro Mantovani et al.
METABOLITES (2021)
Liraglutide Alleviates Hepatic Steatosis and Liver Injury in T2MD Rats via a GLP-1R Dependent AMPK Pathway
Rui Zhou et al.
FRONTIERS IN PHARMACOLOGY (2021)
Effects of Liraglutide on Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
Tiantian Song et al.
DIABETES THERAPY (2021)
Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH
Katharina Luise Hupa-Breier et al.
BIOMEDICINES (2021)
Comprehensive analysis of LncRNAs expression profiles in an in vitro model of steatosis treated with Exendin-4
Khaoula Errafii et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2021)
Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
Thomas G. Cotter et al.
GASTROENTEROLOGY (2020)
Liraglutide ameliorates obesity-related nonalcoholic fatty liver disease by regulating Sestrin2-mediated Nrf2/HO-1 pathway
Xue Han et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2020)
Liraglutide Attenuates Non-Alcoholic Fatty Liver Disease in Mice by Regulating the Local Renin-Angiotensin System
Mengying Yang et al.
FRONTIERS IN PHARMACOLOGY (2020)
Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
Mohammad S. Kuchay et al.
DIABETOLOGIA (2020)
β-catenin mediates the effect of GLP-1 receptor agonist on ameliorating hepatic steatosis induced by high fructose diet
Zhe Gao et al.
EUROPEAN JOURNAL OF HISTOCHEMISTRY (2020)
Spatial expression of glucagon-like peptide 1 receptor and caveolin-1 in hepatocytes with macrovesicular steatosis in non-alcoholic steatohepatitis
Hiroaki Yokomori et al.
BMJ OPEN GASTROENTEROLOGY (2020)
Effects of liraglutide, metformin and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: A randomized trial
Wen-Huan Feng et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Outcomes of liver transplantation for non-alcoholic steatohepatitis: A European Liver Transplant Registry study
Debashis Haldar et al.
JOURNAL OF HEPATOLOGY (2019)
NAFLD in Some Common Endocrine Diseases: Prevalence, Pathophysiology, and Principles of Diagnosis and Management
Amedeo Lonardo et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Fatty acid-binding protein 1 increases steer fat deposition by facilitating the synthesis and secretion of triacylglycerol in liver
Yujuan Wang et al.
PLOS ONE (2019)
Improvement in treatment satisfaction after switching from liraglutide to dulaglutide in patients with type 2 diabetes: A randomized controlled trial
Takahiro Takase et al.
JOURNAL OF DIABETES INVESTIGATION (2019)
Brain leptin reduces liver lipids by increasing hepatic triglyceride secretion and lowering lipogenesis
Martina Theresa Hackl et al.
NATURE COMMUNICATIONS (2019)
Oleic acid-induced perilipin 5 expression and lipid droplets formation are regulated by the PI3K/PPARα pathway in HepG2 cells
Wenxia Zhong et al.
APPLIED PHYSIOLOGY NUTRITION AND METABOLISM (2019)
Glucagon-like peptide 1 (GLP-1)
T. D. Mueller et al.
MOLECULAR METABOLISM (2019)
Non-alcoholic fatty liver disease - A global public health perspective
Zobair M. Younossi
JOURNAL OF HEPATOLOGY (2019)
Effect of Dulaglutide Versus Liraglutide on Glucose Variability, Oxidative Stress, and Endothelial Function in Type 2 Diabetes: A Prospective Study
Hiroe Nagaike et al.
DIABETES THERAPY (2019)
A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant et al.
ENDOCRINOLOGY AND METABOLISM (2019)
Glucagon receptor signaling in metabolic diseases
Nicolai J. Wewer Albrechtsen
PEPTIDES (2018)
GLP-1 receptor agonist ameliorates obesity-induced chronic kidney injury via restoring renal metabolism homeostasis
Chengshi Wang et al.
PLOS ONE (2018)
Wnt/beta-Catenin Signaling in Liver Development, Homeostasis, and Pathobiology
Jacquelyn O. Russell et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 13 (2018)
Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
M. Pilar Valdecantos et al.
SCIENTIFIC REPORTS (2018)
Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function
Jordan Rowlands et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones
Caroline E. Geisler et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Perilipins: a diversity of intracellular lipid droplet proteins
Hiroyuki Itabe et al.
LIPIDS IN HEALTH AND DISEASE (2017)
SREBP-regulated lipid metabolism: convergent physiology - divergent pathophysiology
Hitoshi Shimano et al.
NATURE REVIEWS ENDOCRINOLOGY (2017)
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
Brandon J. Perumpail et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Silencing of FABP1 ameliorates hepatic steatosis, inflammation, and oxidative stress in mice with nonalcoholic fatty liver disease
Takako Mukai et al.
FEBS OPEN BIO (2017)
The Effects of Physical Exercise on Fatty Liver Disease
Dirk J. van der Windt et al.
GENE EXPRESSION (2017)
Reduction of visceral fat by liraglutide is associated with ameliorations of hepatic steatosis, albuminuria, and micro-inflammation in type 2 diabetic patients with insulin treatment: a randomized control trial
Ryotaro Bouchi et al.
ENDOCRINE JOURNAL (2017)
Nutritional Approaches to Achieve Weight Loss in Nonalcoholic Fatty Liver Disease
Christine C. Hsu et al.
ADVANCES IN NUTRITION (2017)
Perilipin Staining Distinguishes Between Steatosis and Nonalcoholic Steatohepatitis in Adults and Children
Rotonya M. Carr et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2017)
Hepatitis B Virus X Protein Induces Hepatic Steatosis by Enhancing the Expression of Liver Fatty Acid Binding Protein
Yun-li Wu et al.
JOURNAL OF VIROLOGY (2016)
The Perilipins: Major Cytosolic Lipid Droplet-Associated Proteins and Their Roles in Cellular Lipid Storage, Mobilization, and Systemic Homeostasis
Alan R. Kimmel et al.
ANNUAL REVIEW OF NUTRITION, VOL 36 (2016)
Pathophysiology of Non Alcoholic Fatty Liver Disease
Salvatore Petta et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Glucagon-like peptide-1 analogue prevents nonalcoholic steatohepatitis in non-obese mice
Takaya Yamamoto et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2016)
Low simvastatin concentrations reduce oleic acid-induced steatosis in HepG2 cells: An in vitro model of non-alcoholic fatty liver disease
Mohammad J. Alkhatatbeh et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Mi Hae Seo et al.
PLOS ONE (2016)
The Glucagon-Like Peptide-1 Analogue Liraglutide Inhibits Oxidative Stress and Inflammatory Response in the Liver of Rats with Diet-Induced Non-alcoholic Fatty Liver Disease
Huiting Gao et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Recent insights into the biological functions of liver fatty acid binding protein 1
GuQi Wang et al.
JOURNAL OF LIPID RESEARCH (2015)
Inactivation of Plin4 downregulates Plin5 and reduces cardiac lipid accumulation in mice
Weiqin Chen et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2013)
The human liver fatty acid binding protein (FABP1) gene is activated by FOXA1 and PPARα; and repressed by C/EBPα: Implications in FABP1 down-regulation in nonalcoholic fatty liver disease
Carla Guzman et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR AND CELL BIOLOGY OF LIPIDS (2013)
Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action
Jonathan E. Campbell et al.
CELL METABOLISM (2013)
GLP-1 Receptor Activation Indirectly Reduces Hepatic Lipid Accumulation But Does Not Attenuate Development of Atherosclerosis in Diabetic Male ApoE(-/-) Mice
Naim Panjwani et al.
ENDOCRINOLOGY (2013)
TRIB2 Acts Downstream of Wnt/TCF in Liver Cancer Cells to Regulate YAP and C/EBPα Function
Jiayi Wang et al.
MOLECULAR CELL (2013)
Foxa1 Reduces Lipid Accumulation in Human Hepatocytes and Is Down-Regulated in Nonalcoholic Fatty Liver
Marta Moya et al.
PLOS ONE (2012)
GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
Edwin T. Parlevliet et al.
PLOS ONE (2012)
Role of Wnt/β-catenin signaling in liver metabolism and cancer
Satdarshan Pal Singh Monga
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2011)
Mitochondrial Carnitine Palmitoyltransferase 1a (CPT1a) Is Part of an Outer Membrane Fatty Acid Transfer Complex
Kwangwon Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2011)
Glucagon-Like Peptide-1 Receptor Is Present on Human Hepatocytes and Has a Direct Role in Decreasing Hepatic Steatosis In Vitro by Modulating Elements of the Insulin Signaling Pathway
Nitika Arora Gupta et al.
HEPATOLOGY (2010)
Medical Hurricane: Health Care Reform and HEPATOLOGY
Michael Charlton
HEPATOLOGY (2009)
Specific Role for Acyl CoA:Diacylglycerol Acyltransferase 1 (Dgat1) in Hepatic Steatosis Due to Exogenous Fatty Acids
Claudio J. Villanueva et al.
HEPATOLOGY (2009)
Diet-induced obesity and hepatic steatosis in L-Fabp(-/-) mice is abrogated with SF, but not PUFA, feeding and attenuated after cholesterol supplementation
Elizabeth P. Newberry et al.
AMERICAN JOURNAL OF PHYSIOLOGY-GASTROINTESTINAL AND LIVER PHYSIOLOGY (2008)
Fatty acid-binding proteins: role in metabolic diseases and potential as drug targets
Masato Furuhashi et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Reversal of diet-induced hepatic steatosis and hepatic insulin resistance by antisense oligonucleotide inhibitors of acetyl-CoA carboxylases 1 and 2
DB Savage et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Decreased liver fatty acid binding capacity and altered liver lipid distribution in mice lacking the liver fatty acid-binding protein gene
GG Martin et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
分享论文
